|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 219.68 USD | -2.52% |
|
-4.53% | -3.86% |
| 03-10 | AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM | |
| 03-09 | AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.22 | 10.06 | 8.07 | 8.49 | 9.81 | |||||
Return on Total Capital | 12.63 | 16.41 | 14.44 | 16.07 | 19.3 | |||||
Return On Equity % | 80.95 | 72.4 | 35.2 | 62.29 | 6.22K | |||||
Return on Common Equity | 80.52 | 72.14 | 34.91 | 61.94 | 15.22K | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 69.19 | 71.53 | 69.21 | 70.37 | 71.62 | |||||
SG&A Margin | 21.13 | 20.82 | 23.76 | 23.41 | 22.31 | |||||
EBITDA Margin % | 49.91 | 54.13 | 48.53 | 47.43 | 47.83 | |||||
EBITA Margin % | 48.48 | 52.79 | 47.14 | 46.07 | 46.59 | |||||
EBIT Margin % | 34.75 | 39.54 | 32.51 | 32.54 | 34.52 | |||||
Income From Continuing Operations Margin % | 20.55 | 20.4 | 8.97 | 7.61 | 6.92 | |||||
Net Income Margin % | 20.54 | 20.39 | 8.95 | 7.59 | 6.91 | |||||
Net Avail. For Common Margin % | 20.41 | 20.29 | 8.87 | 7.52 | 6.84 | |||||
Normalized Net Income Margin | 19.06 | 22.49 | 18.41 | 18.21 | 19.23 | |||||
Levered Free Cash Flow Margin | 34.25 | 39.56 | 41.66 | 35.46 | 29.98 | |||||
Unlevered Free Cash Flow Margin | 36.95 | 41.96 | 44.22 | 38.58 | 32.94 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.38 | 0.41 | 0.4 | 0.42 | 0.45 | |||||
Fixed Assets Turnover | 9.35 | 10.06 | 9.53 | 9.72 | 10.01 | |||||
Receivables Turnover (Average Receivables) | 5.98 | 5.47 | 4.85 | 5.1 | 5.2 | |||||
Inventory Turnover (Average Inventory) | 5.38 | 4.93 | 4.36 | 4.03 | 3.8 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.79 | 0.96 | 0.87 | 0.66 | 0.67 | |||||
Quick Ratio | 0.56 | 0.69 | 0.63 | 0.43 | 0.41 | |||||
Operating Cash Flow to Current Liabilities | 0.65 | 0.84 | 0.6 | 0.49 | 0.44 | |||||
Days Sales Outstanding (Average Receivables) | 61.05 | 66.74 | 75.29 | 71.71 | 70.15 | |||||
Days Outstanding Inventory (Average Inventory) | 67.86 | 74.06 | 83.78 | 90.79 | 96.02 | |||||
Average Days Payable Outstanding | 54.95 | 62.52 | 70.07 | 72.38 | 65.81 | |||||
Cash Conversion Cycle (Average Days) | 73.96 | 78.29 | 88.99 | 90.12 | 100.35 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 502.7 | 373.59 | 582.66 | 2.03K | -2.12K | |||||
Total Debt / Total Capital | 83.41 | 78.88 | 85.35 | 95.3 | 104.95 | |||||
LT Debt/Equity | 420.56 | 348.61 | 511.9 | 1.82K | -1.85K | |||||
Long-Term Debt / Total Capital | 69.78 | 73.61 | 74.99 | 85.55 | 91.5 | |||||
Total Liabilities / Total Assets | 89.47 | 87.55 | 92.28 | 97.51 | 102.41 | |||||
EBIT / Interest Expense | 8.06 | 10.29 | 7.94 | 6.53 | 7.3 | |||||
EBITDA / Interest Expense | 11.72 | 14.24 | 11.99 | 9.64 | 10.25 | |||||
(EBITDA - Capex) / Interest Expense | 11.4 | 13.93 | 11.64 | 9.29 | 9.83 | |||||
Total Debt / EBITDA | 2.73 | 2.03 | 2.27 | 2.52 | 2.31 | |||||
Net Debt / EBITDA | 2.39 | 1.74 | 1.79 | 2.32 | 2.13 | |||||
Total Debt / (EBITDA - Capex) | 2.81 | 2.08 | 2.34 | 2.62 | 2.41 | |||||
Net Debt / (EBITDA - Capex) | 2.45 | 1.78 | 1.85 | 2.4 | 2.22 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 22.69 | 3.3 | -6.44 | 3.71 | 8.57 | |||||
Gross Profit, 1 Yr. Growth % | 22.48 | 3.6 | -9.48 | 5.46 | 10.49 | |||||
EBITDA, 1 Yr. Growth % | 26.52 | 6.84 | -16.12 | 1.37 | 13.35 | |||||
EBITA, 1 Yr. Growth % | 26.71 | 7.12 | -16.45 | 1.36 | 13.77 | |||||
EBIT, 1 Yr. Growth % | 24.4 | 9.89 | -23.07 | 3.81 | 21.2 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 149.87 | 2.56 | -58.86 | -12.05 | -1.24 | |||||
Net Income, 1 Yr. Growth % | 150.04 | 2.55 | -58.91 | -12.03 | -1.22 | |||||
Normalized Net Income, 1 Yr. Growth % | 27.41 | 12.93 | -23.4 | 2.53 | 21.44 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 137.13 | 2.79 | -58.97 | -12.13 | -1.26 | |||||
Accounts Receivable, 1 Yr. Growth % | 13.09 | 12.8 | -0.88 | -2.12 | 15.29 | |||||
Inventory, 1 Yr. Growth % | -5.5 | 14.42 | 14.53 | 2 | 18.42 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.41 | -3.41 | 1.08 | 2.16 | 8.67 | |||||
Total Assets, 1 Yr. Growth % | -2.68 | -5.27 | -2.95 | 0.33 | -0.89 | |||||
Tangible Book Value, 1 Yr. Growth % | -9.72 | -11.39 | -5.83 | 18.26 | -0.16 | |||||
Common Equity, 1 Yr. Growth % | 17.83 | 11.98 | -39.96 | -67.91 | -198.35 | |||||
Cash From Operations, 1 Yr. Growth % | 29.5 | 9.51 | -8.44 | -17.66 | 1.19 | |||||
Capital Expenditures, 1 Yr. Growth % | -1.38 | -11.69 | 11.8 | 25.35 | 24.64 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 14.17 | 14.25 | -1.47 | -11.72 | -5.52 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 12.88 | 12.7 | -1.4 | -9.52 | -4.81 | |||||
Dividend Per Share, 1 Yr. Growth % | 9.71 | 7.53 | 4.9 | 5.01 | 5.72 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 29.97 | 12.58 | -1.69 | -1.49 | 6.11 | |||||
Gross Profit, 2 Yr. CAGR % | 22.7 | 16.6 | -1.67 | -2.29 | 8.09 | |||||
EBITDA, 2 Yr. CAGR % | 31.33 | 21.9 | -3.46 | -3.51 | 4.26 | |||||
EBITA, 2 Yr. CAGR % | 31.32 | 22.32 | -3.46 | -3.58 | 4.36 | |||||
EBIT, 2 Yr. CAGR % | 17.08 | 25.07 | -5.46 | -4.8 | 7.67 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 21.05 | 60.09 | -35.04 | -39.85 | -6.8 | |||||
Net Income, 2 Yr. CAGR % | 21.01 | 60.13 | -35.09 | -39.88 | -6.78 | |||||
Normalized Net Income, 2 Yr. CAGR % | 16.14 | 29.65 | -4.01 | -4.95 | 6.62 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 10.53 | 56.12 | -35.06 | -39.96 | -6.85 | |||||
Accounts Receivable, 2 Yr. CAGR % | 35.58 | 12.95 | 5.74 | -1.5 | 6.23 | |||||
Inventory, 2 Yr. CAGR % | 31.35 | 3.98 | 14.47 | 8.08 | 9.9 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 33.27 | -3.91 | -1.19 | 1.62 | 5.37 | |||||
Total Assets, 2 Yr. CAGR % | 28.23 | -3.98 | -4.12 | -1.32 | -0.28 | |||||
Tangible Book Value, 2 Yr. CAGR % | 48 | -10.56 | -8.65 | 5.53 | 8.66 | |||||
Common Equity, 2 Yr. CAGR % | 37.31 | 14.87 | -18 | -56.1 | -43.82 | |||||
Cash From Operations, 2 Yr. CAGR % | 30.75 | 19.09 | 0.14 | -13.17 | -8.72 | |||||
Capital Expenditures, 2 Yr. CAGR % | 19.4 | -6.68 | -0.64 | 18.38 | 25 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 48.21 | 18.98 | 8.02 | -3.06 | -10.66 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 44.98 | 17.13 | 7.18 | -2.06 | -9.07 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.98 | 8.62 | 6.21 | 4.96 | 5.37 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 19.72 | 20.4 | 5.85 | 0.08 | 1.75 | |||||
Gross Profit, 3 Yr. CAGR % | 15.81 | 17.15 | 7.16 | 0.65 | 1.79 | |||||
EBITDA, 3 Yr. CAGR % | 27.02 | 24.55 | 7.62 | -1.88 | 0.65 | |||||
EBITA, 3 Yr. CAGR % | 27.27 | 24.71 | 7.73 | -1.88 | 0.68 | |||||
EBIT, 3 Yr. CAGR % | 17.88 | 17.24 | 6.36 | -2.47 | 1.44 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 26.64 | 14.54 | 1.78 | -28.14 | -29.04 | |||||
Net Income, 3 Yr. CAGR % | 26.61 | 14.51 | 1.75 | -28.17 | -29.06 | |||||
Normalized Net Income, 3 Yr. CAGR % | 17.03 | 18.03 | 8.79 | -1.87 | 1.19 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 20.79 | 7.88 | 0 | -28.17 | -29.13 | |||||
Accounts Receivable, 3 Yr. CAGR % | 22.83 | 27.51 | 8.14 | 3.05 | 3.81 | |||||
Inventory, 3 Yr. CAGR % | 24.91 | 25.45 | 7.39 | 10.16 | 11.42 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 26.76 | 19.71 | -2.28 | -0.09 | 3.92 | |||||
Total Assets, 3 Yr. CAGR % | 35.15 | 15.92 | -3.64 | -2.66 | -1.18 | |||||
Tangible Book Value, 3 Yr. CAGR % | 27.02 | 24.74 | -9.01 | -0.44 | 3.6 | |||||
Common Equity, 3 Yr. CAGR % | 22.19 | 28.29 | -7.47 | -40.02 | -42.56 | |||||
Cash From Operations, 3 Yr. CAGR % | 19.26 | 23.25 | 9.1 | -6.19 | -8.62 | |||||
Capital Expenditures, 3 Yr. CAGR % | 7.25 | 7.98 | -0.88 | 7.36 | 20.43 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 15.75 | 37.87 | 11.73 | 0.99 | -4.81 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 16.14 | 35.1 | 10.59 | 1.3 | -3.84 | |||||
Dividend Per Share, 3 Yr. CAGR % | 10.37 | 9.16 | 7.36 | 5.81 | 5.21 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 16.99 | 15.52 | 10.65 | 11.11 | 5.95 | |||||
Gross Profit, 5 Yr. CAGR % | 14.4 | 14.04 | 8.47 | 8.95 | 7.47 | |||||
EBITDA, 5 Yr. CAGR % | 21.01 | 21.69 | 14 | 10.44 | 6.7 | |||||
EBITA, 5 Yr. CAGR % | 21.27 | 21.98 | 14.14 | 10.44 | 6.82 | |||||
EBIT, 5 Yr. CAGR % | 15.21 | 17.45 | 8.17 | 5.17 | 7.55 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 14.17 | 17.41 | -3.04 | -11.47 | -1.74 | |||||
Net Income, 5 Yr. CAGR % | 14.16 | 17.39 | -3.08 | -11.5 | -1.75 | |||||
Normalized Net Income, 5 Yr. CAGR % | 15.46 | 18.49 | 8.4 | 5.25 | 8.65 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 12.18 | 14.97 | -5.76 | -14.66 | -2.8 | |||||
Accounts Receivable, 5 Yr. CAGR % | 15.96 | 17.21 | 15.68 | 15 | 7.37 | |||||
Inventory, 5 Yr. CAGR % | 16.72 | 17.4 | 20.63 | 18.19 | 8.39 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 17.66 | 15.14 | 14.74 | 12.12 | 0.71 | |||||
Total Assets, 5 Yr. CAGR % | 17.26 | 14.42 | 17.81 | 8.69 | -2.31 | |||||
Tangible Book Value, 5 Yr. CAGR % | 18.55 | 16.57 | 11.33 | 16.67 | -2.31 | |||||
Common Equity, 5 Yr. CAGR % | 27.15 | 27.62 | 4.17 | -16.46 | -24.21 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.47 | 20.15 | 11.21 | 7.14 | 1.59 | |||||
Capital Expenditures, 5 Yr. CAGR % | 10.44 | 5.61 | 4.02 | 12.03 | 8.75 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 28.36 | 29.87 | 12.76 | 17.92 | 2.48 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 27.43 | 28.57 | 12.62 | 17.08 | 2.56 | |||||
Dividend Per Share, 5 Yr. CAGR % | 17.71 | 16.77 | 8.68 | 7.46 | 6.56 |
- Stock Market
- Equities
- ABBV Stock
- Financials AbbVie Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















